Filing Flows › Karyopharm Therapeutics (KPTI) › Q1 2026 › vs Q4 2025
Karyopharm Therapeutics (KPTI) Q1 2026 vs Q4 2025 (quarter over quarter)
Karyopharm Therapeutics's revenue rose $987K (+3%) from $34.1M in Q4 2025 to $35.1M in Q1 2026. The biggest changes: License and Other +$3.9M (+197%); Product −$2.9M (-9%).
Karyopharm Therapeutics, Q1 2026: revenue $35.1M (+17% year over year), operating margin -76.3%, net loss $22.4M, operating cash flow −$22.7M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Product | $29.2M | $32.1M | −$2.9M | -9% |
| License and Other | $5.9M | $2.0M | $3.9M | +197% |
| Revenue | $35.1M | $34.1M | $987K | +3% |
| Other income, net | $4.4M | −$84.4M | $88.8M | — |
| Net loss | $22.4M | $102M | −$79.8M | -78% |
| Costs & expenses | $61.8M | $136M | −$74.5M | -55% |
| Operating costs | $61.8M | $51.9M | $9.9M | +19% |
| Income tax | $1K | −$67K | $68K | — |
| Research & development | $33.8M | $27.7M | $6.1M | +22% |
| SG&A | $26.7M | $22.8M | $3.9M | +17% |
| Other operating costs | $1.3M | $1.5M | −$139K | -9% |
| Operating cash sources | $25.7M | $15.8M | $10.0M | +63% |
| Depreciation | $12K | $19K | −$7K | -37% |
| Share-based compensation | $3.0M | $3.9M | −$896K | -23% |
| Cash used in operations | $22.7M | $11.8M | $10.9M | +92% |
| Net loss absorbed | $22.4M | $102M | −$79.8M | -78% |
| Working capital & other | $3.4M | −$86.4M | $89.8M | — |
Questions
How much did Karyopharm Therapeutics's revenue grow quarter over quarter in Q1 2026?
Karyopharm Therapeutics's revenue rose $987K (+3%) from $34.1M in Q4 2025 to $35.1M in Q1 2026.
What drove Karyopharm Therapeutics's revenue change in Q1 2026?
License and Other +$3.9M (+197%); Product −$2.9M (-9%).